Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that virtually the same percentage of surveyed rheumatologists selected Amgen/Pfizer/Takeda's Enbrel and Abbott/Eisai's Humira as the most efficacious agent for the treatment of rheumatoid arthritis.
50464
Virtually the same percentage of surveyed rheumatologists selected Enbrel and Humira as the most efficacious agent for the treatment of rheumatoid arthritis
51175
Medical marketing to shift from volume to value based approach in 2013
90631
More experts agree:
9403
New clinical trial search engine launches
109267
How the companies were chosen
122291
Anti-inflammatory drugs reduce effectiveness of antidepressants
81661
Scientists develop safer and more accurate way to administer warfarin
17009
Doctors may be overprescribing drugs for heart conditions
52663
EPharmaSolutions to integrate iTrials longitudinal patient database into CRID
82505
Arthritis drug Vioxx not fit for sale
24642
Drug derived from the hydrangea root shows promise for autoimmune disorders
160909
Eresearch posts two Analyst articles
103487
Emkay recommends `Hold ` on Sun Pharma
174826
Hypercholesterolemia partnering 2007-2012
164422
Qnexa improves quality of life in the obese
134688
Avesthagen scouting for partners for bioactive ingredients
63912
Breakthrough could nip arthritis in the bud